Results 181 to 187 of about 71,664 (187)

Incidence and risk of central nervous system metastases as site of first recurrence in patients with HER2-positive breast cancer treated with adjuvant trastuzumab

Annals of Oncology, 2013
Charles L Shapiro, Mahmoud Abdel-Rasoul, Nancy U Lin   +2 more
exaly  

Pathologic complete response to neoadjuvant chemotherapy with trastuzumab predicts for improved survival in women with HER2-overexpressing breast cancer

Annals of Oncology, 2013
Thomas Buchholz, Wendy A Woodward, A U Buzdar   +2 more
exaly  

Tumor infiltrating lymphocytes are prognostic in triple negative breast cancer and predictive for trastuzumab benefit in early breast cancer: results from the FinHER trial

Annals of Oncology, 2014
Sherene Loi, Mark J. Smyth, Roberto Salgado   +2 more
exaly  

Trastuzumab treatment improves brain metastasis outcomes through control and durable prolongation of systemic extracranial disease in HER2-overexpressing breast cancer patients

British Journal of Cancer, 2009
W K Kang, M J Park, D H Nam
exaly  

Influence of trastuzumab on epirubicin pharmacokinetics in metastatic breast cancer patients

Annals of Oncology, 2003
Lucia Del Mastro
exaly  

A Randomized Phase I Pharmacokinetic Study Comparing Biosimilar Candidate SB3 and Trastuzumab in Healthy Male Subjects

Clinical Therapeutics, 2016
Xavier Pivot, Rainard Fuhr, Yoon Jung Lee   +2 more
exaly  

Cardiovascular events, early discontinuation of trastuzumab, and their impact on survival

Breast Cancer Research and Treatment, 2014
Arti Hurria, Shi-Yi Wang, Cary P Gross
exaly